Health Service Medical Supplies (Costs) Bill Debate

Full Debate: Read Full Debate
Department: Department of Health and Social Care

Health Service Medical Supplies (Costs) Bill

Daniel Zeichner Excerpts
2nd reading: House of Commons & Programme motion: House of Commons
Monday 24th October 2016

(8 years, 1 month ago)

Commons Chamber
Read Full debate Health Service Medical Supplies (Costs) Act 2017 View all Health Service Medical Supplies (Costs) Act 2017 Debates Read Hansard Text Read Debate Ministerial Extracts
Jeremy Hunt Portrait Mr Hunt
- Hansard - - - Excerpts

The hon. Gentleman makes an important point. It will be for this House and the Government to reflect prior to 2019 on whether it is worth carrying on with two schemes, which has been the arrangement for many years. Successive PPRS voluntary agreements have covered the vast majority of sales to the NHS and the statutory scheme has been a back-up for people who do not want to participate in the voluntary scheme. Recently, however, there has been an element of gaming the system whereby more and more firms have been moving from the voluntary scheme into the statutory scheme. The Bill will remove the incentives for them to switch between schemes and will make the benefits to the NHS essentially the same whichever scheme people choose. It will be for this House to reflect on and for the Government to consider whether the dual structure is right going forward.

Daniel Zeichner Portrait Daniel Zeichner (Cambridge) (Lab)
- Hansard - -

The Secretary of State tells us that £1.24 billion has come back through the rebate, but many are puzzled about where that money has been spent. Can the Secretary of State tell us?

Jeremy Hunt Portrait Mr Hunt
- Hansard - - - Excerpts

Absolutely. The money comes back to the Department of Health and is invested in the NHS. Indeed, it would be wonderful if it was more than £1.24 billion, because there is an awful lot of need on the NHS frontline right now; the funds are much needed. Our concern is that companies have been exploiting the differences between the voluntary and statutory schemes, particularly the loophole, which the Bill seeks to close, that if companies have drugs in both schemes, we are unable to regulate at all the prices of the drugs that would ordinarily fall under the statutory scheme. That is why the Bill is so important.